| Industry | C27医药制造业 |
| Market Segment | Main Board |
| Currency | CNY |
| Fiscal Year | 2024 |
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate for injection, cefuroxime tablets/capsules, ampicillin acid, penicillin industrial potassium salt, Touboke Yuekui granules/capsules, remifentanil hydrochloride for injection, sodium cefuroxime for inj...
Full charting with technical indicators, candlestick, and more.
About 国药现代
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate for injection, cefuroxime tablets/capsules, ampicillin acid, penicillin industrial potassium salt, Touboke Yuekui granules/capsules, remifentanil hydrochloride for injection, sodium cefuroxime for injection, ceftriaxone sodium crude salt, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, 7-ACA, amlodipine besylate tablets, cefoperazone dispersible tablets, and amoxicillin capsules. Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 2000 and is headquartered in Shanghai, China.
| Ticker | 600420 |
| Exchange | SSE |
| Sector | 证监会行业分类 |
| Industry | C27医药制造业 |